Oxford Gene Technology Ltd. Initiates Strategic Expansion Plans in North America With the Opening of New York Office and Appointment of U.S. Sales Team

Oxford, UK – 20 November 2012 – Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that it has opened a new office in Tarrytown, New York to support and grow its CytoSure™ cytogenetics arrays and Genefficiency™ next generation sequencing business in the US.

The new office will enable OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further. A number of Sales and Support positions including a Field Application Specialist have been created with more new roles expected in the coming months.

OGT has CytoSure and Genefficiency customers in over 30 countries worldwide and serves a potential clinical cytogenetics market of $400million[1] with rapid future growth forecast. The US is the world’s largest cytogenetics market, and is critical to the development of OGT’s clinical and genomic services business.

Dr Mike Evans, CEO at OGT said, “The opening of the New York office marks a significant milestone for OGT allowing us to offer our US customers even better technical and sales support. Meeting the needs of our customers is our top priority, in a recent survey, 100% of our CytoSure customers said they would recommend OGT to a colleague and we are committed to both continuing and building on this level of expertise and support”.

Dr Madhuri Hegde from Emory University School of Medicine said, “We are delighted that OGT has opened a new US office. The company has a strong reputation and we have always received exceptional service, we look forward to working with the new local support team.”

CytoSure products and Genefficiency services combine advanced microarray and sequencing solutions with class-leading analysis software, enabling clinicians and researchers to accurately detect and interpret chromosomal abnormalities. The CytoSure range focuses on constitutional genetics, molecular genetics and cancer cytogenetics and is a strong growth area for OGT with an increasing global market share.

For more information, please contact:

Oxford Gene Technology

Stephen Archibald, Marketing Communications Manager

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF

T: +44 (0) 1865 856826

F: +44 (0) 1865 848684

E: products@ogt.co.uk

W: www.ogt.co.uk

College Hill (PR Agency for OGT)

Melanie Toyne Sewell / Jen Lewis

College Hill, The Registry, Royal Mint Court, London, EC3N 4QN

T: +44 (0) 20 7457 2029

E:OGT@collegehill.com

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. The company has two trading businesses: Clinical & Genomic Solutions comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Diagnostic Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal, prostate and pancreatic cancer plus the autoimmune disease systemic lupus erythematosus. OGT is currently assessing partnership opportunities to commercialise these biomarker panels.

For more information on the Company, please visit our website at: www.ogt.co.uk

CytoSure: For research use only. Not for use in diagnostic procedures.

Back to news